{"id":266136,"date":"2025-09-30T09:20:13","date_gmt":"2025-09-30T09:20:13","guid":{"rendered":"https:\/\/www.europesays.com\/us\/266136\/"},"modified":"2025-09-30T09:20:13","modified_gmt":"2025-09-30T09:20:13","slug":"why-tariffs-could-ruin-the-pharma-sectors-year-the-armchair-trader","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/266136\/","title":{"rendered":"Why tariffs could ruin the pharma sector’s year \u2013 The Armchair Trader"},"content":{"rendered":"

Autumn in Washington has brought with it a peculiarly American mix of theatre and threat. President Donald Trump has unveiled a 100 per cent tariff on branded and patented pharmaceuticals, due to take effect on October 1st. The measure is meant to force drug manufacturing back onshore. But as with so many tariff salvos, the risks look larger than the supposed rewards.<\/strong><\/p>\n

Nigel Green<\/strong>, chief executive of deVere Group, a large international financial advisory firm, warns that the new duty will ricochet through the global health economy.<\/p>\n

\u201cA tariff of this magnitude on high-value medicines will ripple through every part of the global health economy,\u201d he argues. Rather than reviving domestic industry, he believes it will discourage investment, worsen inflationary pressures and push mobile capital toward friendlier shores. Markets, as ever, are voting with their feet.<\/p>\n

The timing could scarcely be worse<\/p>\n

America\u2019s annual pharmaceutical imports now exceed $200bn, reflecting a finely tuned global supply system where active ingredients and components cross borders multiple times before ending up in a pill bottle. To imagine this vast lattice could be rebuilt overnight is fanciful. \u201cYou can\u2019t rebuild decades of specialised infrastructure overnight,\u201d Green observes drily. Patients may soon discover that the price of \u201cAmerica First\u201d is higher co-payments at the pharmacy.<\/p>\n

Already analysts expect prescription prices to creep up within months, as importers and distributors pass along the new levy. That would deliver another unwelcome shove to inflation, just as the Federal Reserve is gingerly beginning to cut rates. Green sees a \u201cweaker dollar and firmer pricing power in non-US pharmaceutical hubs\u201d as investors reallocate. In other words, capital will not sit about waiting for Washington to change its mind.<\/p>\n

The pharmaceutical front is also only one theatre in a broader campaign. The Trump administration has widened national-security probes into robotics, medical devices and industrial machinery. The message to global investors is clear enough: America is prepared to weaponise tariffs across strategic sectors. Retaliation from trading partners seems almost certain. For fund managers with long horizons, the uncertainty itself is the problem.<\/p>\n

Not surprisingly, emerging markets with robust life-sciences industries are attracting a fresh look. Investors are sniffing around economies with stable trade regimes and open markets, where policy risk feels less capricious. Their currencies could benefit too, while equity flows tilt toward companies insulated from Washington\u2019s trade wars. \u201cThe instinct is to move toward reliability,\u201d says Green.<\/p>\n

Research pipelines could be hit<\/p>\n

The second-order effects are not trivial. Drug development depends on smooth global inputs. If those flows are interrupted, research pipelines could falter, delaying treatments and raising costs. Knock-on effects would ripple to healthcare providers, insurers and ultimately workers whose productivity suffers when medicine becomes scarce.<\/p>\n

America\u2019s reputation as a scientific hub also takes a knock. \u201cRestricting access to world-class ingredients and expertise will not strengthen the US,\u201d Green cautions. \u201cIt will encourage global talent and capital to deepen their commitments elsewhere.\u201d<\/p>\n

The logistical hurdles to Trump\u2019s grand plan are daunting. Building state-of-the-art pharmaceutical plants takes years and billions. Expertise cannot be conjured by presidential decree. In the meantime, shortages and higher costs look inevitable. Markets grasp this better than politicians. As Green notes, \u201ccapital hates uncertainty.\u201d By slapping a sudden, sweeping tariff on a critical sector, Washington may have guaranteed the opposite of what it intends: not the reshoring of drug production, but the offshoring of investment.<\/p>\n

Investors, in short, are unlikely to wait for the president\u2019s next tweet. They are already heading for the exits.<\/p>\n","protected":false},"excerpt":{"rendered":"Autumn in Washington has brought with it a peculiarly American mix of theatre and threat. President Donald Trump…\n","protected":false},"author":3,"featured_media":266137,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[64,135,2175,138802,67,132,68],"class_list":{"0":"post-266136","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-markets","10":"tag-tariffs","11":"tag-the-pharma-sector","12":"tag-united-states","13":"tag-unitedstates","14":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115292512205898075","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/266136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=266136"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/266136\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/266137"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=266136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=266136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=266136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}